Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis

Published:2017-07-25 Issue:1 Volume:17 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Bahmer Thomas^ORCID,Kirsten Anne-Marie,Waschki Benjamin,Rabe Klaus F.,Magnussen Helgo,Kirsten Detlef,Gramm Marco,Hummler Simone,Brunnemer Eva,Kreuter Michael,Watz Henrik

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12890-017-0444-0.pdf

Reference35 articles.

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

2. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.

3. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

4. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171–81.

5. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538–42.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease;Respiratory Investigation;2024-07

2. Supporting self-management for patients with Interstitial Lung Diseases: Utility and acceptability of digital devices;PLOS Digital Health;2024-01-08

3. Physical activity coaching in patients with interstitial lung diseases: A randomized controlled trial;Chronic Respiratory Disease;2024-01

4. Timed Up and Go Identifies Physically Inactive Individuals with Interstitial Lung Disease;2024

5. Machine learning to detect, stage and classify diseases and their symptoms based on inertial sensor data: a mapping review;Physiological Measurement;2023-12-01